| [1] |
Shao B, Yang W, Cao Q. Landscape and predictions of inflammatory bowel disease in china: china will enter the compounding prevalence stage around 2030[J]. Front Public Health, 2022, 10: 1032679.
|
| [2] |
Luo Y, Song Y. Mechanism of antimicrobial peptides: antimicrobial, anti-inflammatory and antibiofilm activities[J]. Int J Mol Sci, 2021, 22(21): 11401.
|
| [3] |
Wong CCM, Zhang L, Wu WKK, et al. Cathelicidin-encoding lactococcus lactis promotes mucosal repair in murine experimental colitis[J]. J Gastroenterol Hepatol, 2017, 32(3): 609-619.
|
| [4] |
Yoo JH, Ho S, Tran DHY, et al. Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis[J]. Cell Mol Gastroenterol Hepatol, 2015, 1(1): 55-74. e1.
|
| [5] |
Maraming P, Klaynongsruang S, Boonsiri P, et al. Anti-metastatic effects of cationic kt2 peptide(a lysine/tryptophan-rich peptide) on human melanoma a375. s2 cells[J]. In Vivo(Athens, Greece), 2021, 35(1): 215-227.
|
| [6] |
Gu D, Nan Q, Miao Y, et al. KT2 alleviates ulcerative colitis by reducing th17 cell differentiation through the mir-302c-5p/stat3 axis[J]. Eur J Cell Biol, 2022, 101(2): 151223.
|
| [7] |
王怡如, 周唯, 蒋笑影, 等. 美沙拉秦干预下IBD小鼠结肠组织的转录组分析[J]. 中国实验动物学报, 2022, 30(1): 7-16.
|
| [8] |
Lv Q, Wang K, Qiao S, et al. Norisoboldine, a natural ahr agonist, promotes treg differentiation and attenuates colitis via targeting glycolysis and subsequent nad+/sirt1/suv39h1/h3k9me3 signaling pathway[J]. Cell Death Dis, 2018, 9(3): 258.
|
| [9] |
Maraming P, Maijaroen S, Klaynongsruang S, et al. Antitumor ability of kt2 peptide derived from leukocyte peptide of crocodile against human hct116 colon cancer xenografts[J]. In Vivo(Athens, Greece), 2018, 32(5): 1137-1144.
|
| [10] |
Liu YJ, Tang B, Wang FC, et al. Parthenolide ameliorates colon inflammation through regulating treg/th17 balance in a gut microbiota-dependent manner[J]. Theranostics, 2020, 10(12): 5225-5241.
|
| [11] |
Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice[J]. J Clin Invest, 2008, 118(7): 2516-2525.
|
| [12] |
Zhang W, Michalowski CB, Beloqui A. Oral delivery of biologics in inflammatory bowel disease treatment[J]. Front Bioeng Biotechnol, 2021, 9: 675194.
|
| [13] |
Quandt J, Arnovitz S, Haghi L, et al. Wnt-β-catenin activation epigenetically reprograms treg cells in inflammatory bowel disease and dysplastic progression[J]. Nat Immunol, 2021, 22(4): 471-484.
|
| [14] |
Martin-Rodriguez O, Gauthier T, Bonnefoy F, et al. Pro-resolving factors released by macrophages after efferocytosis promote mucosal wound healing in inflammatory bowel disease[J]. Front Immunol, 2021, 12: 754475.
|
| [15] |
Jurisic G, Sundberg JP, Detmar M. Blockade of vegf receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement[J]. Inflamm Bowel Dis, 2013, 19(9): 1983-1989.
|
| [16] |
Coburn LA, Horst SN, Allaman MM, et al. L-arginine availability and metabolism is altered in ulcerative colitis[J]. Inflamm Bowel Dis, 2016, 22(8): 1847-1858.
|
| [17] |
Baier J, Gänsbauer M, Giessler C, et al. Arginase impedes the resolution of colitis by altering the microbiome and metabolome[J]. J Clin Invest, 2020, 130(11): 5703-5720.
|
| [18] |
Cheluvappa R. Identification of new potential therapies for colitis amelioration using an appendicitis-appendectomy model[J]. Inflamm Bowel Dis, 2019, 25(3): 436-444.
|
| [19] |
Zhou M, Wang D, Li X, et al. Farnesoid-x receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer[J]. Front Pharmacol, 2022, 13: 1016836.
|